OR WAIT null SECS
March 08, 2024
EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.
The Data Analysis and Real World Interrogation Network, DARWIN EU, is planning to add 10 new data partners in 2024.
March 07, 2024
Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.
The agency has published final guidance documents regarding validation and development of analytical procedures.
March 06, 2024
Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.
The company is expanding GMP capacities at its Frankfurt site to manufacture early clinical-phase peptide APIs.
March 04, 2024
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
March 01, 2024
The partnership will allow for both companies to provide end-to-end biopharmaceutical manufacturing solutions.
CordenPharma’s new starter kits are designed to enable effective formulation in the development of mRNA-based therapeutics.
February 28, 2024
The company is investing more than $250 million into its Bloomington, Ind. Manufacturing site.